Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsUpgradesPrice Target
Leerink Partners analyst Lili Nsongo upgrades enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Outperform and announces $5 price target.
Leerink Partners analyst Lili Nsongo upgrades enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Outperform and announces $5 price target.